What did @extraleonardo actually say?
The creator admitted to a mistake from a previous video, then described two new peptide blends called "Glow" and a second version. The first contains GHK-Cu, BPC-157, and TB-500. The second adds KBV, a lesser-known peptide. He pitched Glow as covering "injury recovery, joint healing, anti-aging, anti-inflammation, skin repair, hair growth." The upgraded version, he said, targets gut inflammation through what he called the "gut skin axis." Both were framed as just-launched products, with the nudge to DM for more info.
Worth noting upfront: this is a sales pitch dressed in educational language. The disclaimer that it's "not medical advice" doesn't change what's actually being communicated, which is that these blends fix your joints, your gut, and your skin. That's a lot of weight to put on a stack of peptides with limited human trial data.
Does the science back this up?
Partially, but not as cleanly as the video implies. GHK-Cu has legitimate research behind it for skin remodeling and wound healing, mostly in vitro and animal models. BPC-157 is interesting in rodent studies for gut repair and tendon healing, but human trials are nearly nonexistent. The gut-skin axis is a real concept in the literature. The framing here, though, overstates certainty.
GHK-Cu (copper peptide) has been studied for collagen synthesis and anti-inflammatory signaling. Pickart et al. published repeatedly on this in journals including Biochemical Pharmacology (2012), showing skin-remodeling effects, but primarily in cell cultures. BPC-157 has shown promise in rodent models of inflammatory bowel disease and tendon healing (Sikiric et al., 2016, Current Pharmaceutical Design), but translating that to human dosing in a blended compound is a significant leap. TB-500, a synthetic fragment of thymosin beta-4, has animal data supporting tissue repair but no published human RCTs. KBV is so obscure that peer-reviewed data is essentially nonexistent in mainstream literature. That's a problem.
What did they get wrong (or right)?
Credit where it's due: the gut-skin axis framing is scientifically grounded. There's solid evidence linking gut microbiome health to skin inflammation outcomes (De Pessemier et al., 2021, Microorganisms). Mentioning it in this context isn't wrong, it's just applied optimistically to a peptide compound that hasn't been tested for that specific pathway in humans.
What's wrong: the stacking of four compounds into a single blend assumes additive or synergistic effects with zero human pharmacokinetic data to support that assumption. The claim that this produces a "cosmetic upgrade" sounds like a cosmetic drug claim, which is a regulatory gray zone. BPC-157 is not approved by the FDA for human use and was placed on the FDA's list of bulk drug substances that cannot be compounded. Selling or promoting it in a blend for human use carries real regulatory risk, and the creator doesn't mention that once.
The admission of an earlier error (no melanotan) is honest, but it also suggests these formulations are being communicated to a large audience before the details are even settled. That's backwards from how medical products should work.
What should you actually know?
If you're curious about peptides for recovery or skin health, the intellectual interest is legitimate. The evidence base, however, is not where the enthusiasm is. Most of the foundational research on BPC-157 and TB-500 comes from animal models, and the jump from rat tendon healing to human "glow" is not a straight line.
GHK-Cu is arguably the most research-supported ingredient in this stack for topical skin use, but systemic effects from injectable or oral forms are less studied. KBV is not a compound you'll find in clinical literature with any meaningful human data.
The bigger issue: blended peptide compounds sold via DM are not subject to the same quality controls as pharmaceutical manufacturing. Purity, sterility, and actual peptide concentration vary enormously between suppliers. If you're considering any peptide therapy, that conversation belongs with a licensed clinician who can review your health history, not a TikTok comment thread.
Bottom line on this stack
The individual ingredients have varying levels of scientific support. GHK-Cu is the strongest on evidence for skin-related outcomes. BPC-157 has interesting mechanistic data but no human trial proof and meaningful FDA restrictions on compounding. TB-500 is promising in animals. KBV is effectively a black box. The combined "Glow" blend exists in a regulatory and evidentiary space that the video does not acknowledge, and the DM-to-purchase model sidesteps the oversight that exists for a reason.